|
|
Adoptive cell transfer therapy for hepatocellular carcinoma |
Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian(), Zhinan Chen() |
Department of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi’an 710032, China |
|
|
Abstract Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. This malignancy is associated with poor prognosis and high mortality. Novel approaches for prolonging the overall survival of patients with advanced HCC are urgently needed. The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltrating lymphocytes and cytokine-induced killer cells, are more effective than those of traditional strategies. Currently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughs in the treatment of hematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell lymphoma. Nevertheless, this approach only provides a modest benefit in the treatment of solid tumors. The clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited. Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe side effects. In this review, we summarized the current application of ACT, the challenges encountered by CAR-T technology in HCC treatment, and some possible strategies for the future direction of immunotherapeutic research.
|
Keywords
adoptive cell transfer therapy
hepatocellular carcinoma
T cell
chimeric antigen receptor
immunotherapy
|
Corresponding Author(s):
Huijie Bian,Zhinan Chen
|
Just Accepted Date: 29 December 2018
Online First Date: 18 January 2019
Issue Date: 12 March 2019
|
|
1 |
RLSiegel, KD Miller, AJemal . Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7–30
https://doi.org/10.3322/caac.21442
pmid: 29313949
|
2 |
WChen, R Zheng, PDBaade, SZhang, HZeng, F Bray, AJemal , XQYu, J He. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66(2): 115–132
https://doi.org/10.3322/caac.21338
pmid: 26808342
|
3 |
AForner, M Reig, JBruix. Hepatocellular carcinoma. Lancet 2018; 391(10127): 1301–1314
https://doi.org/10.1016/S0140-6736(18)30010-2
pmid: 29307467
|
4 |
OVMakarova-Rusher, JMedina-Echeverz, AGDuffy, TFGreten. The yin and yang of evasion and immune activation in HCC. J Hepatol 2015; 62(6): 1420–1429
https://doi.org/10.1016/j.jhep.2015.02.038
pmid: 25733155
|
5 |
TFGreten, XW Wang, FKorangy. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 2015; 64(5): 842–848
https://doi.org/10.1136/gutjnl-2014-307990
pmid: 25666193
|
6 |
RDésert, F Rohart, FCanal , MSicard, MDesille, SRenaud, BTurlin, PBellaud, CPerret, BClément, KALê Cao, OMusso. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017; 66(5): 1502–1518
https://doi.org/10.1002/hep.29254
pmid: 28498607
|
7 |
DGalun, T Srdic-Rajic, ABogdanovic, ZLoncar, MZuvela. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017; 4: 93–103
https://doi.org/10.2147/JHC.S106529
pmid: 28744453
|
8 |
CChen, K Li, HJiang, FSong, H Gao, XPan, BShi, Y Bi, HWang, HWang, Z Li. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother 2017; 66(4): 475–489
https://doi.org/10.1007/s00262-016-1949-8
pmid: 28035433
|
9 |
HGao, K Li, HTu, XPan, H Jiang, BShi, JKong, H Wang, SYang, JGu, Z Li. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014; 20(24): 6418–6428
https://doi.org/10.1158/1078-0432.CCR-14-1170
pmid: 25320357
|
10 |
JMLlovet, S Ricci, VMazzaferro, PHilgard, EGane, JF Blanc, ACde Oliveira, ASantoro, JLRaoul, AForner, MSchwartz, CPorta, SZeuzem, LBolondi, TFGreten, PRGalle, JFSeitz, IBorbath, DHäussinger, TGiannaris, MShan, M Moscovici, DVoliotis, JBruix; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–390
https://doi.org/10.1056/NEJMoa0708857
pmid: 18650514
|
11 |
MKudo, RS Finn, SQin, KHHan, K Ikeda, FPiscaglia, ABaron, JWPark, GHan, J Jassem, JFBlanc, AVogel, DKomov, TRJEvans, CLopez, CDutcus, MGuo, K Saito, SKraljevic, TTamai, MRen, AL. Cheng Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391(10126): 1163–1173
https://doi.org/10.1016/S0140-6736(18)30207-1
pmid: 29433850
|
12 |
JBruix, S Qin, PMerle, AGranito, YHHuang, GBodoky, MPracht, OYokosuka, ORosmorduc, VBreder, RGerolami, GMasi, PJ Ross, TSong, JPBronowicki, IOllivier-Hourmand, MKudo, AL Cheng, JMLlovet, RSFinn, MALeBerre, ABaumhauer, GMeinhardt, GHan; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389(10064): 56–66
https://doi.org/10.1016/S0140-6736(16)32453-9
pmid: 27932229
|
13 |
JMLlovet, R Montal , DSia, RSFinn. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018; 15(10): 599–616
https://doi.org/10.1038/s41571-018-0073-4
pmid: 30061739
|
14 |
HBian, JS Zheng, GNan, RLi, C Chen, CXHu, YZhang, BSun, XL Wang, SCCui, JWu, J Xu, DWei, XZhang, HLiu, W Yang, YDing, JLi, ZN Chen. Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation. J Natl Cancer Inst 2014; 106(9): dju239
https://doi.org/10.1093/jnci/dju239
pmid: 25210200
|
15 |
DPBogdanos, B Gao, MEGershwin. Liver immunology. Compr Physiol 2013; 3(2): 567–598
pmid: 23720323
|
16 |
MRingelhan, D Pfister, TO’Connor, EPikarsky, MHeikenwalder. The immunology of hepatocellular carcinoma. Nat Immunol 2018; 19(3): 222–232
https://doi.org/10.1038/s41590-018-0044-z
pmid: 29379119
|
17 |
ABEl-Khoueiry, B Sangro, TYau, TSCrocenzi, MKudo, C Hsu, TYKim, SPChoo, JTrojan, THWelling 3rd, TMeyer, YKKang, WYeo, A Chopra, JAnderson, CDela Cruz, LLang, J Neely, HTang, HBDastani, IMelero. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389(10088): 2492–2502
https://doi.org/10.1016/S0140-6736(17)31046-2
pmid: 28434648
|
18 |
AXZhu, RS Finn, JEdeline, SCattan, SOgasawara, DPalmer, CVerslype, VZagonel, LFartoux, AVogel, DSarker, GVerset, SLChan, JKnox, B Daniele, ALWebber, SWEbbinghaus, JMa, AB Siegel, ALCheng, MKudo; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19(7): 940–952
https://doi.org/10.1016/S1470-2045(18)30351-6
pmid: 29875066
|
19 |
SARosenberg, MT Lotze, LMMuul, SLeitman, AEChang, SEEttinghausen, YLMatory, JMSkibber, EShiloni, JTVetto, CASeipp, CSimpson, CMReichert. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313(23): 1485–1492
https://doi.org/10.1056/NEJM198512053132327
pmid: 3903508
|
20 |
SARosenberg, BS Packard, PMAebersold, DSolomon, SLTopalian, STToy, P Simon, MTLotze, JCYang, CASeipp, CSimpson, CCarter, SBock, D Schwartzentruber, JPWei, DEWhite. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319(25): 1676–1680
https://doi.org/10.1056/NEJM198812223192527
pmid: 3264384
|
21 |
SARosenberg, NP Restifo. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348(6230): 62–68
https://doi.org/10.1126/science.aaa4967
pmid: 25838374
|
22 |
YNSWong, K Joshi, MPule, KSPeggs, CSwanton, SAQuezada, MLinch. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncol 2017; 18(6): e341–e353
https://doi.org/10.1016/S1470-2045(17)30327-3
pmid: 28593860
|
23 |
SSJiang, Y Tang, YJZhang, DSWeng, ZGZhou, KPan, QZ Pan, QJWang, QLiu, J He, JJZhao, JLi, MS Chen, AEChang, QLi, JC Xia. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget 2015; 6(38): 41339–41349
https://doi.org/10.18632/oncotarget.5463
pmid: 26515587
|
24 |
TTakayama, T Sekine, MMakuuchi, SYamasaki, TKosuge, JYamamoto, KShimada, MSakamoto, SHirohashi, YOhashi, TKakizoe. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356(9232): 802–807
https://doi.org/10.1016/S0140-6736(00)02654-4
pmid: 11022927
|
25 |
XYu, H Zhao, LLiu, SCao, B Ren, NZhang, XAn, J Yu, HLi, XRen. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol 2014; 34(2): 194–203
https://doi.org/10.1007/s10875-013-9976-0
pmid: 24337625
|
26 |
DHui, L Qiang, WJian, ZTi, K Da-Lu. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009; 41(1): 36–41
https://doi.org/10.1016/j.dld.2008.04.007
pmid: 18818130
|
27 |
JHLee, JH Lee, YSLim, JEYeon, TJSong, SJYu, GY Gwak, KMKim, YJKim, JW Lee, JHYoon. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148(7): 1383–1391.e6
https://doi.org/10.1053/j.gastro.2015.02.055
|
28 |
DSWeng, J Zhou, QMZhou, MZhao, QJ Wang, LXHuang, YQLi, SP Chen, PHWu, JCXia. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008; 31(1): 63–71
https://doi.org/10.1097/CJI.0b013e31815a121b
pmid: 18157013
|
29 |
CCPan, ZL Huang, WLi, MZhao, QM Zhou, JCXia, PHWu. Serum α-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin J Cancer 2010; 29(6): 596–602
https://doi.org/10.5732/cjc.009.10580
pmid: 20507732
|
30 |
MZHao, HL Lin, QChen, YBYe, QZ Chen, MSChen. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin J Cancer 2010; 29(2): 172–177
https://doi.org/10.5732/cjc.009.10410
pmid: 20109346
|
31 |
MVMaus, JA Fraietta, BLLevine, MKalos, YZhao, CH June. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014; 32(1): 189–225
https://doi.org/10.1146/annurev-immunol-032713-120136
pmid: 24423116
|
32 |
GGross, Z Eshhar. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol 2016; 56(1): 59–83
https://doi.org/10.1146/annurev-pharmtox-010814-124844
pmid: 26738472
|
33 |
CJochems, J Schlom. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 2011; 236(5): 567–579
https://doi.org/10.1258/ebm.2011.011007
pmid: 21486861
|
34 |
YWada, O Nakashima, RKutami, OYamamoto, MKojiro. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998; 27(2): 407–414
https://doi.org/10.1002/hep.510270214
pmid: 9462638
|
35 |
WMa, L Wu, FZhou, ZHong, Y Yuan, ZLiu. T cell-associated immunotherapy for hepatocellular carcinoma. Cell Physiol Biochem 2017; 41(2): 609–622
https://doi.org/10.1159/000457883
pmid: 28214839
|
36 |
JJMata-Molanes, M Sureda González, B Valenzuela Jiménez, EM Martínez Navarro, A Brugarolas Masllorens. Cancer immunotherapy with cytokine-induced killer cells. Target Oncol 2017; 12(3): 289–299
https://doi.org/10.1007/s11523-017-0489-2
pmid: 28474278
|
37 |
TMorisaki, T Hirano, NKoya, AKiyota, HTanaka, MUmebayashi, HOnishi, MKatano. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res 2014; 34(8): 4529–4538
pmid: 25075096
|
38 |
KPan, YQ Li, WWang, LXu, YJ Zhang, HXZheng, JJZhao, HJQiu, DS Weng, JJLi, QJWang, LXHuang, JHe, SP Chen, MLKe, PHWu, MS Chen, SPLi, JCXia, YX Zeng. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 2013; 20(13): 4305–4311
https://doi.org/10.1245/s10434-013-3144-x
pmid: 23892527
|
39 |
LCSchmeel, FC Schmeel, CCoch, IGSchmidt-Wolf. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2015; 141(5): 839–849
https://doi.org/10.1007/s00432-014-1864-3
pmid: 25381063
|
40 |
QZPan, QJ Wang, JQDan, KPan, YQ Li, YJZhang, JJZhao, DSWeng, YTang, LX Huang, JHe, SPChen, MLKe, MS Chen, MSWicha, AEChang, YXZeng, QLi, JC Xia. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Sci Rep 2015; 5(1): 9202
https://doi.org/10.1038/srep09202
pmid: 25776856
|
41 |
JNBrudno, JN Kochenderfer. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 2018; 15(1): 31–46
https://doi.org/10.1038/nrclinonc.2017.128
pmid: 28857075
|
42 |
CHJune, RS O’Connor, OUKawalekar, SGhassemi, MCMilone. CAR T cell immunotherapy for human cancer. Science 2018; 359(6382): 1361–1365
https://doi.org/10.1126/science.aar6711
pmid: 29567707
|
43 |
DWLee, JN Kochenderfer, MStetler-Stevenson, YKCui, CDelbrook, SAFeldman, TJFry, R Orentas, MSabatino, NNShah, SMSteinberg, DStroncek, NTschernia, CYuan, H Zhang, LZhang, SARosenberg, ASWayne, CLMackall. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385(9967): 517–528
https://doi.org/10.1016/S0140-6736(14)61403-3
pmid: 25319501
|
44 |
JHartmann, M Schüßler-Lenz, ABondanza, CJBuchholz. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 2017; 9(9): 1183–1197
https://doi.org/10.15252/emmm.201607485
pmid: 28765140
|
45 |
YLiu, X Chen, WHan, YZhang. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc) 2017; 53(11): 597–608
https://doi.org/10.1358/dot.2017.53.11.2725754
pmid: 29451276
|
46 |
PVormittag, R Gunn, SGhorashian, FSVeraitch. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol 2018; 53: 164–181
https://doi.org/10.1016/j.copbio.2018.01.025
pmid: 29462761
|
47 |
SDi, Z Li. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Sci China Life Sci 2016; 59(4): 360–369
https://doi.org/10.1007/s11427-016-5025-6
pmid: 26968709
|
48 |
CWMount, RG Majzner, SSundaresh, EPArnold, MKadapakkam, SHaile, LLabanieh, EHulleman, PJWoo, SP Rietberg, HVogel, MMonje, CLMackall. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med 2018; 24(5): 572–579
https://doi.org/10.1038/s41591-018-0006-x
pmid: 29662203
|
49 |
ADFesnak, CH June, BLLevine. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 2016; 16(9): 566–581
https://doi.org/10.1038/nrc.2016.97
pmid: 27550819
|
50 |
BLZhang, DY Qin, ZMMo, YLi, W Wei, YSWang, WWang, YQ Wei. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci 2016; 59(4): 340–348
https://doi.org/10.1007/s11427-016-5027-4
pmid: 26965525
|
51 |
ZJiang, X Jiang, SChen, YLai, X Wei, BLi, SLin, S Wang, QWu, QLiang, QLiu, M Peng, FYu, JWeng, X Du, DPei, PLiu, Y Yao, PXue, PLi. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol 2017; 7: 690
https://doi.org/10.3389/fimmu.2016.00690
pmid: 28123387
|
52 |
ASaied, L Licata, RABurga, MThorn, EMcCormack, BFStainken, EOAssanah, PDKhare, RDavies, NJEspat, RPJunghans, SCKatz. Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Ther 2014; 21(11): 457–462
https://doi.org/10.1038/cgt.2014.50
pmid: 25277132
|
53 |
RAMorgan, JC Yang, MKitano, MEDudley, CMLaurencot, SARosenberg. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18(4): 843–851
https://doi.org/10.1038/mt.2010.24
pmid: 20179677
|
54 |
RABurga, M Thorn, GRPoint, PGuha, CT Nguyen, LALicata, RPDeMatteo, AAyala, NJoseph Espat, RPJunghans, SCKatz. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 2015; 64(7): 817–829
https://doi.org/10.1007/s00262-015-1692-6
pmid: 25850344
|
55 |
WALim, CH June. The principles of engineering immune cells to treat cancer. Cell 2017; 168(4): 724–740
https://doi.org/10.1016/j.cell.2017.01.016
pmid: 28187291
|
56 |
KAdachi, Y Kano, TNagai, NOkuyama, YSakoda, KTamada. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 2018; 36(4): 346–351
https://doi.org/10.1038/nbt.4086
pmid: 29505028
|
57 |
JJMilner, C Toma, BYu, KZhang, KOmilusik, ATPhan, DWang, AJ Getzler, TNguyen, SCrotty, WWang, ME Pipkin, AWGoldrath. Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours. Nature 2017; 552(7684): 253–257
https://doi.org/10.1038/nature24993
pmid: 29211713
|
58 |
VFako, XW Wang. The status of transarterial chemoembolization treatment in the era of precision oncology. Hepat Oncol 2017; 4(2): 55–63
https://doi.org/10.2217/hep-2017-0009
pmid: 28989699
|
59 |
EUnitt, A Marshall, WGelson, SMRushbrook, SDavies, SLVowler, LSMorris, NColeman, GJAlexander. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45(2): 246–253
https://doi.org/10.1016/j.jhep.2005.12.027
pmid: 16580084
|
60 |
KFYoong, G McNab, SGHübscher, DHAdams. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998; 160(8): 3978–3988
pmid: 9558106
|
61 |
TFlecken, N Schmidt, SHild, EGostick, ODrognitz, RZeiser, PSchemmer, HBruns, TEiermann, DAPrice, HEBlum, CNeumann-Haefelin, RThimme. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 2014; 59(4): 1415–1426
https://doi.org/10.1002/hep.26731
pmid: 24002931
|
62 |
JPrieto, I Melero, BSangro. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015; 12(12): 681–700
https://doi.org/10.1038/nrgastro.2015.173
pmid: 26484443
|
63 |
JAJoyce, DT Fearon. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348(6230): 74–80
https://doi.org/10.1126/science.aaa6204
pmid: 25838376
|
64 |
GZhou, D Sprengers, PPCBoor, MDoukas, HSchutz, SMancham, APedroza-Gonzalez, WGPolak, Jde Jonge, MGaspersz, HDong, K Thielemans, QPan, IJJNM, MJ Bruno, JKwekkeboom. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology 2017; 153(4): 1107–1119.e10
https://doi.org/10.1053/j.gastro.2017.06.017
|
65 |
JRen, X Liu, CFang, SJiang, CHJune, YZhao. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 2017; 23(9): 2255–2266
https://doi.org/10.1158/1078-0432.CCR-16-1300
pmid: 27815355
|
66 |
SSNeelapu, S Tummala, PKebriaei, WWierda, CGutierrez, FLLocke, KVKomanduri, YLin, N Jain, NDaver, JWestin, AMGulbis, MELoghin, JFde Groot, SAdkins, SEDavis, KRezvani, PHwu, EJ Shpall. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15(1): 47–62
https://doi.org/10.1038/nrclinonc.2017.148
pmid: 28925994
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|